UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2020

Commission File Number: 001-36515

Materialise NV

Technologielaan 15 3001 Leuven Belgium (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

This Form 6-K is incorporated by reference into the registrant's Registration Statement on Form F-3 (File No. 333-213649).

Second Quarter 2020 Results

Except as otherwise required by the context, references to "Materialise," "Company," "we," "us" and "our" are to Materialise NV and its subsidiaries.

Second Quarter 2020 Results

Total revenue for the second quarter of 2020 decreased 21.3% to 38,117 kEUR compared to 48,404 kEUR for the second quarter of 2019.

Revenue from our Materialise Software segment increased 2.4% to 9,540 kEUR for the second quarter of 2020 from 9,320 kEUR for the same quarter last year.

Revenue from our Materialise Medical segment decreased 19.3% to 11,735 kEUR for the second quarter of 2020 compared to 14,546 kEUR for the same period in 2019. Compared to the second quarter of 2019, revenues from our medical software grew 6.7% and revenues from medical devices and services decreased 31.8%.

Revenue from our Materialise Manufacturing segment decreased 31.7% to 16,777 kEUR for the second quarter of 2020 from 24,550 kEUR for the second quarter of 2019.

Gross profit was 19,986 kEUR, or 52.4% of total revenue, for the second quarter of 2020 compared to 26,527 kEUR, or 54.8% of total revenue, for the second quarter of 2019.

Research and development ("R&D"), sales and marketing ("S&M") and general and administrative ("G&A") expenses decreased, in the aggregate, 18.5% to 22,705 kEUR for the second quarter of 2020 from 27,861 kEUR for the second quarter of 2019. Specific cost reduction initiatives in S&M and G&A resulted in decreases compared to the second quarter of 2019 of 22.9% and 24.3% respectively, while R&D expenses decreased only 0.9%.

Net other operating income was 892 kEUR compared to 1,370 kEUR for the second quarter of 2019.

Operating result decreased to (1,827) kEUR from 36 kEUR for the second quarter of 2019.

Net financial result was (295) kEUR compared to (190) kEUR for the second quarter of 2019. The share in result of joint venture amounted to 0 kEUR compared to (82) kEUR for the same period in 2019.

The second quarter of 2020 contained income tax income of 191 kEUR, compared to an income tax expense of (61) kEUR in the second quarter of 2019.

As a result of the above, net loss for the second quarter of 2020 was (1,932) kEUR, compared to (297) kEUR for the same period in 2019. Total comprehensive loss for the second quarter of 2020, which includes exchange differences on translation of foreign operations, was (2,977) kEUR compared to (727) kEUR for the 2019 period.

Adjusted EBITDA decreased to 3,382 kEUR from 5,059 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the second quarter of 2020 was 8.9% compared to 10.5% for the second quarter of 2019.

Segment EBITDA from our Materialise Software segment increased to 3,756 kEUR from 2,055 kEUR while the segment EBITDA margin (segment EBITDA divided by segment revenue) was 39.4% compared to 22.1% for the prior-year period.

Segment EBITDA from our Materialise Medical segment decreased to 1,139 kEUR compared to 2,738 kEUR while the segment EBITDA margin was 9.7% compared to 18.8% for the second quarter of 2019.

Segment EBITDA from our Materialise Manufacturing segment decreased to 650 kEUR from 2,835 kEUR while the segment EBITDA margin was 3.9% compared to 11.5% for the second quarter of 2019.

At June 30, 2020, we had cash and equivalents of 125,454 kEUR compared to 128,897 kEUR at December 31, 2019. Gross debt amounted to 121,549 kEUR, compared to 127,939 kEUR at December 31, 2019. As a result, our net cash position increased 2,947 kEUR during the first half year of 2020.

Cash flow from operating activities for the second quarter of 2020 was 7,053 kEUR compared to 4,760 kEUR for the same period in 2019. Total capital expenditures for the second quarter of 2020 amounted to 3,398 kEUR.

Net shareholders' equity at June 30, 2020 was 132,847 kEUR compared to 142,675 kEUR at December 31, 2019.

Non-IFRS Measures

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of longterm investment and financing decisions, rather than the performance of the Company's day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the Company's business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The Company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The Company's calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1198, the reference rate of the European Central Bank on June 30, 2020.

About Materialise

Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise's open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world.

Consolidated income statements (Unaudited)

	For the three months ended June 30,			For the six months ended June 30,		
In 000	2020 U.S.\$	2020	2019 €	2020 €	2019 €	
Revenue	42,684	€ 38,117	• 48,404	€ 84,362	• 95,519	
Cost of sales	(20,303)	(18,131)	(21,877)	(39,744)	(43,413)	
Gross profit	22,380	19,986	26,527	44,618	52,106	
Gross profit as % of revenue	52,4%	52.4%	54,8%	52,9%	54,6%	
Research and development expenses	(6,769)	(6,045)	(6,100)	(12,572)	(11,786)	
Sales and marketing expenses	(11,379)	(10,161)	(13,173)	(22,789)	(25,252)	
General and administrative expenses	(7,277)	(6,499)	(8,588)	(13,696)	(16,184)	
Net other operating income (expenses)	999	892	1,370	1,575	2,627	
Operating (loss) profit	(2.046)	(1,827)	36	(2,864)	1,511	
Financial expenses	(717)	(640)	(313)	(2,461)	(1,509)	
Financial income	386	345	123	845	728	
Share in loss of joint venture			(82)	(39)	(205)	
(Loss) profit before taxes	(2,377)	(2,123)	(236)	(4,519)	524	
Income taxes	214	191	(61)	(267)	(1,126)	
Net (loss) profit for the period	(2,163)	(1,932)	(297)	(4,786)	(601)	
Net (loss) profit attributable to:						
The owners of the parent	(2,098)	(1,874)	(297)	(4,681)	(601)	
Non-controlling interest	(65)	(58)	—	(104)	_	
Earnings per share attributable to owners of the parent						
Basic	(0.04)	(0.04)	(0.01)	(0.09)	(0.01)	
Diluted	(0.04)	(0.04)	(0.01)	(0.09)	(0.01)	
Weighted average basic shares outstanding	53,194	53,194	52,891	53,194	52,891	
Weighted average diluted shares outstanding	53,194	53,194	52,891	53,194	52,891	

Consolidated statements of comprehensive income (Unaudited)

In 000		tree months June 30, 2020 €	ended 2019 €	For the months er June 3 2020 €	nded
Net profit (loss) for the period	(2,163)	(1,932)	(297)	(4,786)	(602)
Other comprehensive income					
Exchange difference on translation of foreign operations	(1,170)	(1,045)	(430)	(6,787)	157
Other comprehensive income (loss), net of taxes	(1, 170)	(1,045)	(430)	(6,787)	157
Total comprehensive income (loss) for the year, net of taxes	(3.333)	(2,977)	(727)	(11.573)	(445)
Total comprehensive income (loss) attributable to:					
The owners of the parent	(3,074)	(2,745)	(727)	(10,470)	(445)
Non-controlling interest	(260)	(232)	_	(1,103)	—

Consolidated statement of financial position (Unaudited)

In 000	As of June 30, 2020 €	As of December 31, 2019 €
Assets		
Non-current assets		
Goodwill	19,222	20,174
Intangible assets	24,964	27,395
Property, plant & equipment	88,683	90,331
Right-of-Use assets	9,883	10,586
Investments in joint ventures	—	39
Deferred tax assets	234	192
Other non-current assets	10,244	9,391
Total non-current assets	153,410	158,108
Current assets		
Inventories	11,682	12,696
Trade receivables	30,253	40,322
Other current assets	9,631	9,271
Cash and cash equivalents	125,454	128,897
Total current assets	177,021	191,186
Total assets	330,431	349,294

In 000	As of June 30, 	As of <u>December 31,</u> <u>2019</u> €
Equity and liabilities		
Equity		
Share capital	3,068	3,066
Share premium	138,229	138,090
Consolidated reserves	(4,876)	(195)
Other comprehensive income	(5,789)	(1.394)
Equity attributable to the owners of the parent	130,632	139,567
Non-controlling interest	2,216	3,107
Total equity	132,847	142,675
Non-current liabilities		
Loans & borrowings	97,590	104,673
Lease liabilities	6,132	6,427
Deferred tax liabilities	5,687	5,747
Deferred income	4,970	5,031
Other non-current liabilities	671	696
Total non-current liabilities	115,051	122,575
Current liabilities		
Loans & borrowings	14,331	13,389
Lease liabilities	3,496	3,449
Trade payables	15,641	18,516
Tax payables	2,560	3,363
Deferred income	28,157	27,641
Other current liabilities	18,348	17,686
Total current liabilities	82,533	84,044
Total equity and liabilities	330,431	349,294

Consolidated statement of cash flows (Unaudited)

in 000	For the six months e 2020	<u>nded June 30,</u> 2019
	€	€
Operating activities		
Net (loss) profit for the period	(4,786)	(602)
Non-cash and operational adjustments		
Depreciation of property, plant & equipment	7,410	6,950
Amortization of intangible assets	2,284	2,229
Share-based payment expense	0	197
Loss (gain) on disposal of property, plant & equipment	46	134
Movement in provisions	4	20
Movement reserve for bad debt	181	(116)
Financial income	(845)	(171)
Financial expense	2,453	1,232
Impact of foreign currencies	0	(288)
Share in loss of a joint venture (equity method)	39	205
(Deferred) income taxes	266	1,126
Other	36	(196)
Working capital adjustment & income tax paid		
Decrease (increase) in trade receivables and other receivables	8,962	(4,466)
Decrease (increase) in inventories	1,220	(43)
Increase (decrease) in trade payables and other payables	(1,843)	3,737
Income tax paid	(1,102)	(1,108)
Net cash flow from operating activities	14,326	8,840

in 000	For the six months 2020	<u>ended June 30,</u> 2019
	€	€
Investing activities		
Purchase of property, plant & equipment	(5,756)	(4,827)
Purchase of intangible assets	(687)	(1,457)
Proceeds from the sale of property, plant & equipment & intangible assets (net)	72	(3)
Convertible loan to third party	(300)	(2,500)
Investments in joint-ventures	_	_
Interest received	_	_
Net cash flow used in investing activities	(6,671)	(8,787)
Financing activities		
Proceeds from loans & borrowings	15	3,000
Repayment of loans & borrowings	(5,813)	(5,818)
Repayment of finance leases	(1,823)	(2,765)
Capital increase	140	_
Interest paid	(1,178)	(934)
Other financial income (expense)	(617)	(292)
Net cash flow from (used in) financing activities	(9,276)	(6,809)
Net increase of cash & cash equivalents	(1,621)	(6,756)
Cash & cash equivalents at beginning of the year	128,897	115,506
Exchange rate differences on cash & cash equivalents	(1.822)	115
Cash & cash equivalents at end of the year	125,454	108,865

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

		For the three months ended June 30,		x months une 30,
In 000	2020 €	2019 €	2020 €	2019
Net profit (loss) for the period	(1,932)	(297)	(4,786)	(601)
Income taxes	(191)	61	266	1,126
Financial expenses	640	313	2,461	1,509
Financial income	(345)	(123)	(845)	(728)
Share in loss of joint venture		82	39	205
Depreciation and amortization	4,979	4,649	9,694	9,178
EBITDA	3,152	4,685	6,829	10,691
Non-cash stock-based compensation expense (1)	(231)	(374)	(156)	(196)
Acquisition-related expenses business combinations	—		—	
ADJUSTED EBITDA	3,382	5,059	6,985	10,888

(1) Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees.

Segment P&L (Unaudited)

In 000	Materialise <u>Software</u> €	Materialise <u>Medical</u> €	Materialise <u>Manufacturing</u> €	Total <u>segments</u> €	Unallocated (1)(2) €	Consoli- <u>dated</u> €
For the three months ended June 30, 2020						
Revenues	9,540	11,735	16,777	38,052	29	38,117
Segment (adj) EBITDA	3,756	1,139	650	5,546	(2,164)	3,382
Segment (adj) EBITDA %	39.4%	9.7%	3.9%	11.6%		
For the three months ended June 30, 2019						
Revenues	9,320	14,546	24,550	48,415	(11)	48,404
Segment (adj) EBITDA	2,055	2,738	2,835	7,629	(2,570)	5,059
Segment (adj) EBITDA %	22.1%	18.8%	11.5%	15.8%		
In 000	Materialise <u>Software</u> €	Materialise <u>Medical</u> €	Materialise <u>Manufacturing</u> €	Total <u>segments</u> €	Unallocated (1)(2) €	Consoli- dated €
In 000 For the six months ended June 30, 2020				segments	(1)(2)	dated
				segments	(1)(2)	dated
For the six months ended June 30, 2020	Software_ €	<u>Medical</u> €	<u>Manufacturing</u> €	<u>segments</u> €	<u>(1)(2)</u> €	dated €
For the six months ended June 30, 2020 Revenues	Software € 19,361	<u>Medical</u> € 27,380	Manufacturing € 37,592	segments € 84,333	<u>(1)(2)</u> € 29	<u>dated</u> € 84,362
For the six months ended June 30, 2020 Revenues Segment (adj) EBITDA	<u>Software</u> € 19,361 6,401	<u>Medical</u> € 27,380 3,595	<u>Manufacturing</u> € 37,592 1,768	segments € 84,333 11,765	<u>(1)(2)</u> € 29	<u>dated</u> € 84,362
For the six months ended June 30, 2020 Revenues Segment (adj) EBITDA Segment (adj) EBITDA %	<u>Software</u> € 19,361 6,401	<u>Medical</u> € 27,380 3,595	<u>Manufacturing</u> € 37,592 1,768	segments € 84,333 11,765	<u>(1)(2)</u> € 29	<u>dated</u> € 84,362
For the six months ended June 30, 2020 Revenues Segment (adj) EBITDA Segment (adj) EBITDA % For the six months ended June 30, 2019	<u>Software</u> € 19,361 6,401 33.1%	<u>Medical</u> € 27,380 3,595 13.1%	<u>Manufacturing</u> € 37,592 1,768 4.7%	segments € 84,333 11,765 14.0%	(1)(2) € 29 (4,779)	<u>dated</u> € 84,362 6,985

(1) Unallocated Revenues consist of occasional one-off sales in our core competencies not allocated to any of our segments.

(2) Unallocated Segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense) and the added non-cash share-based compensation expenses that acquisition expenses of business combinations that are included in Adjusted EBITDA.

Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)

		For the three months ended June 30,		x months une 30,
In 000	2020	2019	2020	2019
	€	€	€	€
Net profit (loss) for the period	(1,932)	(297)	(4,786)	(601)
Income taxes	(191)	61	266	1,126
Financial cost	640	313	2,461	1,509
Financial income	(345)	(123)	(845)	(728)
Share in loss of joint venture		82	39	205
Operating profit	(1,827)	36	(2,864)	1,511
Depreciation and amortization	4,979	4,649	9,694	9,178
Corporate research and development	687	502	1,478	1,014
Corporate headquarter costs	2,781	3,108	5,173	5,777
Other operating income (expense)	(1.074)	(501)	(1,716)	(1,107)
Segment EBITDA	5,546	7,629	11,765	16,058

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MATERIALISE NV

By: /s/ Wilfried Vancraen

Name: Wilfried Vancraen Title: Chief Executive Officer

Date: July 30, 2020